New collaboration launches at ISPOR 2024, offering pharmaceutical and biotech companies rapid access to unique, customizable data and expert guidance to bridge HTA evidence gaps.
London, UK, 18 November 2024 – Leading Market Access consultancy Decisive Consulting and, uMed, a pioneering healthcare evidence-generation and technology company, have announced a strategic partnership aimed at accelerating market access initially for therapies targeting Cardiometabolic Disease (CMD) and Parkinson’s Disease (PD).
Combining uMed’s cutting-edge data collection and linkage capabilities within these disease areas, with Decisive Consulting’s extensive expertise in navigating healthcare technology assessments (HTAs) and evolving evidence needs worldwide, this collaboration promises to address key challenges that hinder therapies from reaching patients.
Launching officially at ISPOR Europe 2024 in November, the partnership offers a unique consultancy service that empowers pharmaceutical, biotechnology and medical device companies with fast, efficient access to both retrospective and prospective patient data, alongside expert-driven strategic recommendations. This approach is designed to identify and address critical evidence gaps, helping customers shape their market access strategies and ultimately prove value to HTA bodies.
As the healthcare industry faces increasing pressure to prove the value of high-cost treatments, and medicines with uncertain long-term benefits, this partnership will directly address several key industry challenges.
HTA decisions rely on comprehensive and high-quality clinical data, but real-world evidence is often lacking or incomplete. uMed’s platform links real-world, clinical and patient-generated data to provide a dynamic, customisable dataset that can be smartly adapted to meet specific HTA needs, unlike traditional static databases.
Furthermore uMed’s direct-to-patient data collection captures outcomes that are difficult to quantify, such as quality of life and patient satisfaction, providing a clearer picture of treatment impact.
With access to pre-consented patient cohorts, organizations will be able to rapidly gather insights that enable quicker decisions on strategic positioning and evidence requirements, providing competitive advantage in a fast-moving market.
By aligning this unique, patient-generated data with comprehensive evaluations of evidence gaps from experienced HTA consultants who understand both the scientific and economic landscape, the partnership enables companies to mitigate gaps in their evidence base, ultimately enhancing their ability to meet HTA criteria for clinical and cost-effectiveness. Customers can also expect to receive full support for the publication of evidence, helping to translate data into actionable insights for HTA submissions.
Dr. Matt Wilson, CEO & Founder of uMed, commented: “This partnership enables us to become an essential partner to our customers by extending our services beyond the provision of custom datasets, to now also offer meaningful insights that substantiate value propositions and improve chances of market success. This is especially timely as we see the exponential development of innovative therapies for obesity and associated cardiometabolic conditions.”
Esther Nzenza, CEO & Founder of Decisive Consulting, added: “This strategic collaboration enhances our shared capabilities beyond evidence strategy and into evidence action, allowing identification of gaps and rapid delivery of targeted insights to support a range of different needs. In fast-evolving fields such as CVM, addressing these gaps is often crucial for market access and HTA success. Together, we empower clients to find and proactively address evidence shortfalls, strengthen their value propositions, and improve their ability to navigate complex market access requirements”
Dr. Matt Wilson, CEO & Founder of uMed, commented: “This partnership enables us to become an essential partner to our customers by extending our services beyond the provision of custom datasets, to now also offer meaningful insights that substantiate value propositions and improve chances of market success. This is especially timely as we see the exponential development of innovative therapies for obesity and associated cardiometabolic conditions.”
Esther Nzenza, CEO & Founder of Decisive Consulting, added: “This strategic collaboration enhances our shared capabilities beyond evidence strategy and into evidence action, allowing identification of gaps and rapid delivery of targeted insights to support a range of different needs. In fast-evolving fields such as CVM, addressing these gaps is often crucial for market access and HTA success. Together, we empower clients to find and proactively address evidence shortfalls, strengthen their value propositions, and improve their ability to navigate complex market access requirements”
About uMed
uMed is a leading health data platform that combines real-world evidence with patient-generated data, bridging critical evidence gaps in life science research. With a pre-consented patient cohort, uMed accelerates the collection of high-quality, customizable data for clinical and real-world studies.
About Decisive Consulting
Decisive Consulting is a global market access consultancy with a proven track record of successfully supporting the launch of innovative medicines and technologies. Decisive specialises in helping clients anticipate requirements and navigate complexity, ensuring products meet the clinical and cost-effectiveness criteria set by HTA bodies and other decision makers.
For media inquiries, please contact:
Lucy White
Communications Manager, uMed
Samantha Shannon
Partnerships Manager, Decisive Consulting
